Clinical Trial Update: Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase I trial of TH-302 (evofosfamide) in combination with gemcitabine and nab-paclitaxel for pancreatic cancer was terminated, with results posted on 2017-12…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• TH-302 (evofosfamide) (evofosfamide)

Snippet

Sponsor: ImmunoGenesis | Conditions: Pancreatic Cancer | Phase 1 | Status: TERMINATED | Results posted: 2017-12-15